development of evidence-based guidelines and tested/validated intervention tools; (5) training professionals; and (6) building capacity for systems of services in states.

Likely Respondents: Grantees funded by HRSA under the CAAI will be the respondents for this data collection activity. The programs to be evaluated are listed below.

1. Training Programs

- Leadership Education in Neurodevelopmental Disabilities (LEND) training programs with fortythree grantees;
- Developmental Behavioral Pediatrics (DBP) training programs with ten grantees; and
- A National Combating Autism Interdisciplinary Training Resource Center grantee.

2. Research Networks Program

• Three Autism Intervention Research Networks that focus on intervention research, guideline development, and information dissemination; and • 20 R40 Maternal and Child Health (MCH) Autism Intervention Research Program grantees that support research on evidence-based practices for interventions to improve the health and well-being of children and adolescents with ASD and other DD.

3. State Implementation Program Grants for Improving Services for Children and Youth With ASD and Other DD

- Nine grantees will implement state autism plans and develop models for improving the system of care for children and youth with ASD and other DD:
- Four grantees will design state plans for improving the system for children and youth with ASD and other DDs; and
- A State Public Health Coordinating Resource Center grantee.

The data gathered through this evaluation will be used to:

• Evaluate the grantees' performance in achieving the objectives of the CAAI during the three year grant period;

- Assess the short- and intermediateterm impacts of the grant programs on children and families affected by ASD and other DD; and
- Measure the CAAI outputs and outcomes for the Report to Congress.

Burden Statement: Burden in this context means the time expended by persons to generate, maintain, retain, disclose or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install and utilize technology and systems for the purpose of collecting, validating and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the table below.

TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS

Grant program/form name	Number of respondents	Number of responses per respondent	Total responses	Average burden per response (in hours)	Total burden hours
LEND interview Protocol	43	1	43	1	43
DBP Interview Protocol	10	1	10	1	10
State Implementation Program Interview Protocol 1	13	1	13	1 1	13
State Implementation Program Questionnaire	13	1	13	.75	9.75
Research Network Interview Protocol	3	1	3	1	3
Research Program R40 Interview Protocol	20	1	20	1	20
Research Network Questionnaire	3	1	3	3	9
Resource Centers Interview Protocol	2	1	2	1	2
Total	107		107		109.75

¹ Although a total of 22 state grants have been awarded to date, states that were awarded grants in 2008 and 2009 were interviewed during the previous evaluation. We are seeking clearance to interview only the 13 states that were awarded grants in 2011.

Dated: December 5, 2013.

Bahar Niakan,

Director, Division of Policy and Information Coordination.

[FR Doc. 2013-29509 Filed 12-10-13; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44) and Clinical Trial Planning Grant (R34).

Date: January 7, 2014. Time: 12:00 p.m. to 4:00 p.m. *Agenda:* To review and evaluate grant applications.

Place: National Institutes of Health, Room 3131, 6700–B Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Betty Poon, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, NIAID/NIH/DHHS, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, 301– 402–6891, poonb@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS).

Dated: December 4, 2013.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–29468 Filed 12–10–13; 8:45 am]

BILLING CODE 4140-01-P